Verona Pharma PLC Holding(s) in Company (3219T)
04 January 2017 - 9:16PM
UK Regulatory
TIDMVRP
RNS Number : 3219T
Verona Pharma PLC
04 January 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
-----------------------------------------------------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
------------------------------------------------------------- --------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-----------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------- -------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
-------------------------------------------------------------- -------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
-------------------------------------------------------------- -------------------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------- -------------------------------
Other (please
specify):
------------------------------------------------------------ -------------------------------
3. Full name of person(s) Wales Life Sciences Investment
subject to the Fund LP
notification obligation:
(iii)
------------------------------------------------------------- --------------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
------------------------------------------------------------- --------------------------------
5. Date of the transaction 3 January 2017
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- --------------------------------
6. Date on which issuer 3 January 2017
notified:
------------------------------------------------------------- --------------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 4.1%
------------------------------------------------------------- --------------------------------
8. Notified details:
------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if
possible
using
the ISIN
CODE
----------- ---------------------------------- -----------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
----------- ---------------- ---------------- -------------- ---------------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
----------- ------------ ------------ -------------- -------------- ------------ ------------ -----------
Ordinary 207,500,000 207,500,000 105,500,000 105,500,000 4.1%
---------------- ---------------- -------------- -------------- ------------ ------------ -----------
B: Qualifying Financial Instruments
------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
--------------- -------------- -------------------------------- ------------------------------ ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
------------- -------------- -------------- ---------------- ------------------------------ -----------------------
Nominal Delta
------------- -------------- -------------- ---------------- ------------------------------ ------------ ---------
Total (A+B+C)
------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------- ---------------------------------------------------------------------
105,500,000 4.1%
------------------------------------------------- ---------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-----------------------------------------------------------------------------
Wales Life Sciences Investment Fund LP, as a stand-alone
entity, previously held 8.1% of voting rights of Verona
Pharma plc. After this disposal it holds 4.1%
The Wales Life Sciences Investment Fund LP is managed
by Arthurian Life Sciences Ltd.
Arix Bioscience plc is the parent of Arthurian Life
Sciences Ltd.
Arix Bioscience plc separately holds 2.5% of the voting
rights which remain unchanged.
Proxy Voting:
-----------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- --------------
11. Number of voting rights proxy
holder will cease to hold:
------------------------------------------------------------- --------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- --------------
13. Additional information:
------------------------------------------------------------- --------------
14. Contact name: Shafia Zahoor
------------------------------------------------------------- --------------
15. Contact telephone number: 020-7290-1057
------------------------------------------------------------- --------------
Note: Annex should only be submitted to the FCA not
the issuer
Annex: Notification of major interests in share
A: Identity of the persons or legal entity subject to
the notification obligation
----------------------------------------------------------------------
Full name Wales Life Sciences Investment
(including legal form of Fund LP
legal entities)
------------------------------------- -------------------------------
Contact address 20 Berkeley Square, London
(registered office for legal W1J 6EQ
entities)
------------------------------------- -------------------------------
Phone number & email 020-7290-1057
------------------------------------- -------------------------------
Other useful information
(at least legal representative
for legal persons)
------------------------------------- -------------------------------
B: Identity of the notifier, if applicable
----------------------------------------------------------------------
Full name Shafia Zahoor
------------------------------------- -------------------------------
Contact address 20 Berkeley Square, London
W1J 6EQ
------------------------------------- -------------------------------
Phone number & email 020-7290-1057
shafia@arixbioscience.com
------------------------------------- -------------------------------
Other useful information
(e.g. functional relationship
with the person or legal
entity subject to the notification
obligation)
------------------------------------- -------------------------------
C: Additional information
----------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUWGGUPMGUC
(END) Dow Jones Newswires
January 04, 2017 05:16 ET (10:16 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles